{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:42:19Z","timestamp":1784590939157,"version":"3.55.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100023551","name":"Cystic Fibrosis Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023551","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001631","name":"University College Dublin - National University of Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001631","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jcf.2026.02.015","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T16:26:45Z","timestamp":1774024005000},"page":"521-537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Changes to serum lipids, BMI and body composition in adults with cystic fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor (ETI): A scoping review"],"prefix":"10.1016","volume":"25","author":[{"given":"Anna","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2593-0960","authenticated-orcid":false,"given":"Clodagh","family":"Landers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3644-1580","authenticated-orcid":false,"given":"Niamh","family":"Lucey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2326-3009","authenticated-orcid":false,"given":"Oonagh","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8986-677X","authenticated-orcid":false,"given":"Clare A","family":"Corish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2026.02.015_bib0001","article-title":"Radiological and long-term clinical response to Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis with advanced lung disease","volume":"10","author":"Aalbers","year":"2023","journal-title":"Adolesc Adults Cyst Fibrosis. Heliyon"},{"issue":"5","key":"10.1016\/j.jcf.2026.02.015_bib0035","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1164\/rccm.200505-840OE","article-title":"*Cystic fibrosis since 1938*","volume":"173","author":"Davis","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.02.015_bib0063","series-title":"*Cystic fibrosis*","author":"Hodson","year":"2012"},{"issue":"1","key":"10.1016\/j.jcf.2026.02.015_bib0103","first-page":"112","article-title":"*Nutritional assessment and management of cystic fibrosis*","volume":"15","author":"Ritivoiu","year":"2023","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.jcf.2026.02.015_bib0120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1569-1993(02)00032-2","article-title":"*Nutrition in patients with cystic fibrosis: a European consensus*","volume":"1","author":"Sinaasappel","year":"2002","journal-title":"J Cyst Fibrosis"},{"issue":"1","key":"10.1016\/j.jcf.2026.02.015_bib0085","first-page":"53","article-title":"*Nutritional status in patients with cystic fibrosis*","volume":"24","author":"Matel","year":"2009","journal-title":"Nutr Clin Pract"},{"issue":"1","key":"10.1016\/j.jcf.2026.02.015_bib0088","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-277X.1994.tb00405.x","article-title":"*Energy expenditure and energy intake in cystic fibrosis*","volume":"7","author":"Morrison","year":"1994","journal-title":"J Hum Nutr Dietet"},{"key":"10.1016\/j.jcf.2026.02.015_bib0005","article-title":"*CFTR modulators and their impact on cystic fibrosis management*","volume":"250","author":"Bacalhau","year":"2023","journal-title":"Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.jcf.2026.02.015_bib0151","first-page":"1199","article-title":"*Clinical efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in patients with cystic fibrosis*","volume":"15","author":"Zaher","year":"2021","journal-title":"Expert Rev Respir Med"},{"issue":"4","key":"10.1016\/j.jcf.2026.02.015_bib0138","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/1747-0080.12882","article-title":"Dietary intake and quality among adults with cystic fibrosis: a systematic review","volume":"81","author":"Thornton","year":"2024","journal-title":"Nutr Dietet"},{"issue":"5","key":"10.1016\/j.jcf.2026.02.015_bib0012","first-page":"673","article-title":"Weight gain and metabolic complications in cystic fibrosis patients treated with CFTR modulators","volume":"19","author":"Bonhoure","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.02.015_bib0029","unstructured":"CFRI (2025) CFRI 2024 annual report. Available at: https:\/\/cfri.ie\/wp-content\/uploads\/2025\/12\/CFRI-2024-Annual-Report-eISSN.pdf (Accessed: 14 January 2026)."},{"key":"10.1016\/j.jcf.2026.02.015_bib0092","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"*The PRISMA 2020 statement: an updated guideline for reporting systematic reviews*","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jcf.2026.02.015_bib0134","doi-asserted-by":"crossref","DOI":"10.3390\/genes12081178","article-title":"*Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor therapy in three subjects with the cystic fibrosis genotype Phe508del\/unknown and advanced lung disease*","author":"Terlizzi","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jcf.2026.02.015_bib0076","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/S1569-1993(22)00377-0","article-title":"Treatment benefits of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis carrying non-F508del mutations","volume":"21","author":"Livnat","year":"2022","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0090","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcf.2026.02.015_bib0094","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0020","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jcf.2023.06.010","article-title":"Body mass index and nutritional intake following Elexacaftor\/Tezacaftor\/Ivacaftor modulator therapy in adults with cystic fibrosis","volume":"22","author":"Caley","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"23","key":"10.1016\/j.jcf.2026.02.015_bib0024","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.3390\/jcm11236900","article-title":"Cystic fibrosis patients with F508del\/minimal function genotype: laboratory and nutritional evaluations after one year of Elexacaftor\/Tezacaftor\/Ivacaftor treatment","volume":"11","author":"Carnovale","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcf.2026.02.015_bib0055","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12931-023-02451-0","article-title":"Heterogeneity of weight gain after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis","volume":"24","author":"Gramegna","year":"2023","journal-title":"Respir Res"},{"key":"10.1016\/j.jcf.2026.02.015_bib0070","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.clnu.2023.10.015","article-title":"*A prospective study to assess the impact of a novel CFTR therapy combination on body composition in patients with cystic fibrosis with F508del mutation*","volume":"42","author":"Knott-Torcal","year":"2023","journal-title":"Clin Nutr"},{"key":"10.1016\/j.jcf.2026.02.015_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2023.102247","article-title":"Real world outcomes of CFTR modulator therapy in australian adults and children","volume":"82","author":"Kuek","year":"2023","journal-title":"Pulm Pharmacol Ther,"},{"key":"10.1016\/j.jcf.2026.02.015_bib0075","article-title":"Elexacaftor-Tezacaftor-Ivacaftor in 2 cystic fibrosis adults homozygous for M1101k with end-stage lung disease","volume":"46","author":"Leung","year":"2023","journal-title":"Respir Med Case Rep,"},{"key":"10.1016\/j.jcf.2026.02.015_bib0080","article-title":"Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes","volume":"33","author":"Lurquin","year":"2023","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.jcf.2026.02.015_bib0095","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcf.2023.06.002","article-title":"*Weight a minute: exploring the effect on weight and body composition after the initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in adults with CF*","volume":"22","author":"Proud","year":"2023","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0105","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jcf.2023.06.001","article-title":"Clinical and functional efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis carrying the N1303k mutation","volume":"22","author":"Sadras","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.02.015_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107406","article-title":"Long-term clinical outcomes of Elexacaftor\/Tezacaftor\/Ivacaftor therapy in adults with cystic fibrosis and advanced pulmonary Disease","volume":"219","author":"Savi","year":"2023","journal-title":"Respir Med"},{"key":"10.1016\/j.jcf.2026.02.015_bib0111","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/liv.15544","article-title":"Increase of liver stiffness and altered bile acid metabolism after triple CFTR modulator initiation in children and young adults with cystic fibrosis","volume":"43","author":"Schnell","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jcf.2026.02.015_bib0112","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S1569-1993(23)00256-4","article-title":"Ws12.04 an \"expanding area\" of interest - the effect of Elexacaftor\/Tezacaftor\/Ivacaftor (ETI) therapy on body image and weight","volume":"22","author":"Scholz","year":"2023","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0116","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ppul.26261","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis","volume":"58","author":"Sheikh","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.02.015_bib0128","article-title":"Impact of Elexacaftor\/Tezacaftor\/Ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German Cf registry","volume":"32","author":"Sutharsan","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jcf.2026.02.015_bib0130","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clnesp.2023.08.028","article-title":"Effect of 18 months elexacaftor-tezacaftor-ivacaftor on body mass index and glycemic control in adults with cystic fibrosis","volume":"58","author":"Taelman","year":"2023","journal-title":"Clin Nutr ESPEN"},{"key":"10.1016\/j.jcf.2026.02.015_bib0135","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1002\/alr.23209","article-title":"Olfaction, body mass index, and quality of life with cystic fibrosis combination therapy","volume":"13","author":"Tervo","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jcf.2026.02.015_bib0003","article-title":"The changing landscape of treatment for cystic fibrosis related diabetes","volume":"35","author":"Amini","year":"2024","journal-title":"Clin Transl Endocrinol"},{"key":"10.1016\/j.jcf.2026.02.015_bib0045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40348-024-00178-6","article-title":"Changes in vitamins and trace elements after initiation of highly effective CFTR modulator therapy in children and adults with cystic fibrosis - a real-life insight","volume":"11","author":"Fabricius","year":"2024","journal-title":"Mol Cell Pediatr"},{"key":"10.1016\/j.jcf.2026.02.015_bib0066","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0304555","article-title":"Anti-inflammatory effects of Elexacaftor\/Tezacaftor\/Ivacaftor in adults with cystic fibrosis heterozygous for F508del","volume":"19","author":"Jarosz-Griffiths","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.jcf.2026.02.015_bib0093","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/ppul.26823","article-title":"Impact of Elexacaftor\/Tezacaftor\/Ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index","volume":"59","author":"Patel","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.02.015_bib0124","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000538606","article-title":"Improved nutritional outcomes and gastrointestinal symptoms in adult cystic fibrosis patients treated with Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"42","author":"Stastna","year":"2024","journal-title":"Dig Dis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0126","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/ppul.26982","article-title":"Predicting weight gain in patients with cystic fibrosis on triple combination modulator","volume":"59","author":"Stewart","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.02.015_bib0142","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2023.05.009","article-title":"Sex differences in outcomes of people with cystic fibrosis treated with Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"23","author":"Wang","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.02.015_bib0143","first-page":"1","article-title":"Longitudinal evaluation of physical fitness in adults with cystic fibrosis in the era of CFTR-modulating-therapies","author":"Welsner","year":"2024","journal-title":"Res Q Exerc Sport"},{"key":"10.1016\/j.jcf.2026.02.015_bib0038","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1513\/AnnalsATS.202102-220RL","article-title":"Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in advanced cystic fibrosis lung disease","volume":"18","author":"Djavid","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2026.02.015_bib0061","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/S1569-1993(22)00379-4","article-title":"The effectiveness of CFTR modulators in people with cystic fibrosis and rare mutations - a real-world study","volume":"21","author":"Hanger","year":"2022","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0083","first-page":"11","article-title":"Early effects of elexacaftor-tezacaftor-ivacaftor therapy on magnETIc resonance imaging in patients with cystic fibrosis and advanced lung disease","author":"Macconi","year":"2022","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.jcf.2026.02.015_bib0114","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/nu14020310","article-title":"The relationship between body composition, dietary intake, physical activity, and pulmonary status in adolescents and adults with cystic fibrosis","volume":"14","author":"Scully","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.jcf.2026.02.015_bib0152","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221144211","article-title":"Impact of Elexacaftor\/Tezacaftor\/Ivacaftor on depression and anxiety in cystic fibrosis","volume":"16","author":"Zhang","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1245885","article-title":"Qualitative and quantitative evaluation of computed tomography changes in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: a retrospective observational study","volume":"14","author":"Dettmer","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2026.02.015_bib0039","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1016\/S1569-1993(23)00693-8","article-title":"Does Elexacaftor\/Tezacaftor\/Ivacaftor triple therapy significantly raise blood lipids? A longitudinal cohort study","volume":"22","author":"Docherty","year":"2023","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1178009","article-title":"Elexacaftor-Tezacaftor-Ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study","volume":"14","author":"Fila","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2026.02.015_bib0050","first-page":"10","article-title":"Nutritional status and circulating levels of fat-soluble vitamins in cystic fibrosis patients: a cohort study and evaluation of the effect of CFTR modulators","author":"Francalanci","year":"2023","journal-title":"Children (Basel)"},{"key":"10.1016\/j.jcf.2026.02.015_bib0060","series-title":"Long-term follow-up of health-related quality of life and short-term intervention with CFTR modulator therapy in adults with cystic fibrosis: evaluation of changes over several years with or without 33 weeks of CFTR modulator therapy","first-page":"11","author":"Gruber","year":"2023"},{"key":"10.1016\/j.jcf.2026.02.015_bib0140","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1016\/S1569-1993(23)00672-0","article-title":"Step-wise introduction of Elexacaftor\/Tezacaftor\/Ivacaftor in patients with cystic fibrosis and liver cirrhosis child-pugh A Or B using clinical- and therapeutic drug monitoring: a case series","volume":"22","author":"Vonk","year":"2023","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0002","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jcf.2024.02.008","article-title":"Clinical efficacy of CFTR modulator therapy in people with cystic fibrosis carrying the I1234v mutation","volume":"23","author":"Aluma","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.02.015_bib0027","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-68511-7","article-title":"Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del\/CFTR variant genotype after Elexacaftor\/Tezacaftor\/Ivacaftor treatment","volume":"14","author":"Castaldo","year":"2024","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.jcf.2026.02.015_bib0043","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25052770","article-title":"Comprehensive assessment of CFTR modulators\u2019 therapeutic efficiency for N1303K variant","volume":"25","author":"Efremova","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2026.02.015_bib0046","series-title":"People with cystic fibrosis and rare mutations","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor","author":"Fainardi","year":"2024"},{"issue":"7","key":"10.1016\/j.jcf.2026.02.015_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28508","article-title":"Real-world effectiveness of elexacaftor\/tezacaftor\/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis","volume":"10","author":"Keens","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.jcf.2026.02.015_bib0078","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/phar.2903","article-title":"Real world study on elexacaftor-tezacaftor-ivacaftor impact on cholesterol levels in adults with cystic fibrosis","volume":"44","author":"Lonabaugh","year":"2024","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jcf.2026.02.015_bib0064","first-page":"56","article-title":"Clinical response to Elexacaftor\/Tezacaftor\/Ivacaftor for cystic fibrosis patients in a compassionate use setting","author":"Hofland","year":"2020","journal-title":"Euro Respir J"},{"key":"10.1016\/j.jcf.2026.02.015_bib0068","first-page":"S135","article-title":"October. Highly effective CFTR modulator therapy affects body composition in people with cystic fibrosis","volume":"55","author":"Keith","year":"2020"},{"key":"10.1016\/j.jcf.2026.02.015_bib0069","first-page":"S81","article-title":"October. Factors associated with weight gain and improvement in FEV1 in people with cystic fibrosis on elexacaftor-tezacaftor-ivacaftor","volume":"55","author":"Khare","year":"2020"},{"key":"10.1016\/j.jcf.2026.02.015_bib0137","first-page":"294","article-title":"Clincal outcomes with Elexacaftor\/Tezacaftor\/Ivacaftor in cystic fibrosis patients with advanced lung disease","volume":"55","author":"Thompson","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.02.015_bib0032","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S1569-1993(21)00971-1","article-title":"Short-term impact of kaftrio on weight and use of pancreatic enzyme replacement therapy","volume":"20","author":"Connolly","year":"2021","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0009","first-page":"203","article-title":"A one-year retrospective analysis of the effect of elexacaftor-tezacaftor-ivacaftor on lung function in cystic fibrosis patients with advanced lung disease","author":"Bermingham","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.02.015_bib0086","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/S1569-1993(21)01621-0","article-title":"Assessment of body composition in an adult cystic fibrosis clinic in the era of CFTR modulators","volume":"20","author":"Mcdonagh","year":"2021","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0091","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/S1569-1993(21)01620-9","article-title":"Changes in weight, body mass index, pancreatic enzyme dose, and vitamin levels after cystic fibrosis transmembrane conductance regulator modulator therapy initiation","volume":"20","author":"Nowak","year":"2021","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0107","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.4713","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor as rescue therapy in a patient with the cystic fibrosis genotype F508del\/G1244e","volume":"9","author":"Salvatore","year":"2021","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.jcf.2026.02.015_bib0117","doi-asserted-by":"crossref","first-page":"A1446","DOI":"10.1016\/j.chest.2021.07.1325","article-title":"Impact of cystic fibrosis transmembrane conductance regulator modulator elexacaftor-tezacaftor-ivacaftor on lung function, bmi, bacterial colonization, and adaptive immune responses in patients with cystic fibrosis","volume":"160","author":"Sheikh","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2026.02.015_bib0007","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1016\/S1569-1993(22)00492-1","article-title":"Body mass index change in adult patients with cystic fibrosis following the introduction of triple CFTR therapy Elexacaftor\/Tezacaftor\/Ivacaftor: a regional adult cystic fibrosis centre experience","volume":"21","author":"Barrett","year":"2022","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0062","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/S1569-1993(22)00537-9","article-title":"A retrospective observational study of the effects of kaftrio on the current cohort of patients at Nottingham University Hospitals NuhTrust","volume":"21","author":"Hardiman","year":"2022","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0081","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/S1569-1993(22)00899-2","article-title":"Metabolic changes after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in a Northern Ireland population with cystic fibrosis","volume":"21","author":"Lynch","year":"2022","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0102","first-page":"S159","article-title":"Effect of elexacaftor-tezaftor-ivacaftor on a west of Ireland cohort of patients with cystic fibrosis (Cf) and comparison of \"smart\" monitoring of patients compared to traditional lab and clinic based measurements","volume":"191","author":"Ridge","year":"2022","journal-title":"Ir J Med Sci"},{"key":"10.1016\/j.jcf.2026.02.015_bib0109","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S1569-1993(22)00711-1","article-title":"Impact of Elexacaftor\/Tezacaftor\/Ivacaftor therapy on older adults with cystic fibrosis","volume":"21","author":"Sapru","year":"2022","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0125","first-page":"60","article-title":"Triple CFTR modulator therapy is associated with improved endocrine pancreatic function in patients with cystic fibrosis","author":"Steinack","year":"2022","journal-title":"Euro Respir J"},{"key":"10.1016\/j.jcf.2026.02.015_bib0127","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1016\/S1569-1993(22)00919-5","article-title":"Impact of cystic fibrosis transmembrane conductance regulator modulator therapy on nutritional status, hepatic steatosis, and dyslipidemia","volume":"21","author":"Sundaram","year":"2022","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0131","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1016\/S1569-1993(22)00918-3","article-title":"Hold the mayo on the Elexacaftor\/Tezacaftor\/Ivacaftor special! A single-center experience","volume":"21","author":"Talish","year":"2022","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0010","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/S1569-1993(23)00706-3","article-title":"Evolution of the body composition of people with cystic fibrosis 6 months after the introduction of treatment with Elexacaftor\/Tezacaftor\/Ivacaftor (ETI)","volume":"22","author":"Bernard","year":"2023","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0017","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S1569-1993(23)00339-9","article-title":"Eps5.09 changes in nutritional status and muscular strength in adult patients with cystic fibrosis (Pwcf) treated with Elexacaftor\/Tezacaftor\/Ivacaftor (ETI)","volume":"22","author":"Brignole","year":"2023","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0031","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/S1569-1993(23)00720-8","article-title":"Impact of one year of treatment with Elexacaftor\/Tezacaftor\/Ivacaftor on clinical outcomes in adult patients with cystic fibrosis - first experience from croatia","volume":"22","author":"Cickovic","year":"2023","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0072","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1016\/j.pan.2023.06.469","article-title":"The positive nutritional and gastrointestinal effects of Elexacaftor\/Tezacaftor\/Ivacaftor in the treatment of cystic fibrosis","volume":"23","author":"Kunovsky","year":"2023","journal-title":"Pancreatology"},{"key":"10.1016\/j.jcf.2026.02.015_bib0079","doi-asserted-by":"crossref","first-page":"S392","DOI":"10.1016\/S1569-1993(23)01632-6","article-title":"Real-world impact of elexacaftor-tezacaftor ivacaftor on quality of life of adults with cystic fibrosis","volume":"22","author":"Love","year":"2023","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0106","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/S1569-1993(23)00440-X","article-title":"A Brazilian experience of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis carrying at least one copy of F508del-CFTR","volume":"22","author":"Salomao","year":"2023","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0149","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S1569-1993(23)00427-7","article-title":"Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis with normal\/near normal Fev1 (\u226570%)","volume":"22","author":"Yaacoby-Bianu","year":"2023","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0041","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/S1569-1993(23)00704-X","article-title":"Body composition changes after Elexacaftor\/Tezacaftor\/Ivacaftor treatment in adults with cystic fibrosis -single centre experience","volume":"22","author":"Dugac","year":"2023","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0132","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/S1569-1993(23)00418-6","article-title":"Changes in body composition in adult cystic fibrosis patients within six months of initiation Elexacaftor\/Tezacaftor\/Ivacaftor therapy in Argentina","volume":"22","author":"Tamburri","year":"2023","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0044","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1569-1993(24)00149-8","article-title":"Impact of CFTR modulator therapy on cardiovascular risk in cystic fibrosis: a longitudinal cohort analysis","volume":"23","author":"England","year":"2024","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0015","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1016\/S1569-1993(24)00635-0","article-title":"Maintenance of nutritional parameters improvements over two years of Elexacaftor\/Tezacaftor\/Ivacaftor (ETI) treatment according to severity of cystic fibrosis (CF) pulmonary disease","volume":"23","author":"Brignole","year":"2024","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0006","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1016\/S1569-1993(24)00639-8","article-title":"Two years of Elexacaftor\/Tezacaftor\/Ivacaftor has consistent effects on body composition in homozygous and heterozygous F50del patients with cystic fibrosis","volume":"23","author":"BarETIc","year":"2024","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0065","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S1569-1993(24)00282-0","article-title":"Eps8.03 impact of 12 months of Elexacaftor\/Tezacaftor\/Ivacaftor on pulmonary function and exercise capacity in patients with cystic fibrosis","volume":"23","author":"Jagerstedt","year":"2024","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0073","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1569-1993(24)00150-4","article-title":"Ws07.05 cardiometabolic risk factors in individuals with cystic fibrosis undergoing elexacaftor\/tezacaftor \/ivacaftor therapy","volume":"23","author":"Leonardi","year":"2024","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0084","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S1569-1993(24)00372-2","article-title":"Effectiveness of ETI in people with cystic fibrosis and no F508del CFTR variant: a multicenter study in Greece","volume":"23","author":"Manika","year":"2024","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0101","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S1569-1993(24)00284-4","article-title":"Eps8.05 a case series of muscle strength and body composition from no modulator to highly effective modulator (ETI) in adults with cystic fibrosis","volume":"23","author":"Reilly","year":"2024","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0104","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/S1569-1993(24)00255-8","article-title":"Eps5.06 is Elexacaftor\/Tezacaftor\/Ivacaftor therapy associated with lipid profile changes in a scottish adult cystic fibrosis (Cf) centre?","volume":"23","author":"Robb","year":"2024","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0121","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1016\/S1569-1993(24)00651-9","article-title":"Long-term impact of Elexacaftor\/Tezacaftor\/Ivacaftor (ETI) therapy on weight gain and body composition in adult cystic fibrosis patients: a retrospective analysis","volume":"23","author":"Smuljic","year":"2024","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0133","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/S1569-1993(24)00363-1","article-title":"Long term indications and clinical outcomes in sustained dose reduction strategies for Elexacaftor\/Tezacaftor\/Ivacaftor (ETI): a case series","volume":"23","author":"Tangney","year":"2024","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0147","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/S1569-1993(24)00678-7","article-title":"Kaftrio and the octogenarian: a case study","volume":"23","author":"Wood","year":"2024","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0008","first-page":"290","article-title":"A multi-center retrospective analysis of the clinical efficacy of elexacaftortezacaftor-ivacaftor in patients with advanced lung disease","volume":"55","author":"Bermingham","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.02.015_bib0013","first-page":"201","article-title":"Promising results with Elexacaftor\/Tezacaftor\/Ivacaftor use in cystic fibrosis patients with advanced lung disease: beyond the clinical trial inclusion criteria","author":"Bowen","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.02.015_bib0057","first-page":"S227","article-title":"October. Elexacaftor-Tezacaftor-Ivacaftor improves mental health and function in patients with severe lung disease: a first case series in Italy","volume":"55","author":"Graziano","year":"2020"},{"key":"10.1016\/j.jcf.2026.02.015_bib0119","first-page":"273","article-title":"Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis","volume":"55","author":"Simpson","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"Suppl. 2","key":"10.1016\/j.jcf.2026.02.015_bib0148","first-page":"221","article-title":"Disease modulation by Elexacaftor\/Tezacaftor\/Ivacaftor in cystic fibrosis patients with severe lung disease","volume":"55","author":"Wright","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.02.015_bib0056","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S1569-1993(21)01443-0","article-title":"18 effect of clinical initiation of Elexacaftor\/Tezacaftor\/Ivacaftor on glucose homeostasis in patients with cystic fibrosis","volume":"20","author":"Granados","year":"2021","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0025","first-page":"205","article-title":"The impact of Elexacaftor\/Tezacaftor\/Ivacaftor on the protease- antiprotease balance in cystic fibrosis airways","author":"Casey","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.02.015_bib0030","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S1569-1993(23)00243-6","article-title":"Increasing cardiovascular risk in adults with cystic fibrosis related diabetes receiving CFTR modulator therapy (Elexacaftor\/Tezacaftor\/Ivacaftor)","volume":"22","author":"Chan","year":"2023","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0036","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1569-1993(23)00450-2","article-title":"Discrepancy between in vitro CFTR functional analysis and clinical response to Elexacaftor\/Tezacaftor\/Ivacaftor (ETI) in a homozygous S364p (C.1090t>C) patient with cystic fibrosis","volume":"22","author":"De Sevin","year":"2023","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0051","doi-asserted-by":"crossref","first-page":"S400","DOI":"10.1016\/S1569-1993(23)01645-4","article-title":"Efficacy and tolerability of elexacaftor-tezacaftor-ivacaftor in a cohort of older people with cystic fibrosis","volume":"22","author":"Garcia","year":"2023","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0115","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1016\/S1569-1993(23)00690-2","article-title":"Comparing faecal elastase, pancreatic enzyme doses, hba1c and insulin doses in adult cystic fibrosis patients pre- and 6 months postcommencement of kaftrio","volume":"22","author":"Sheibani","year":"2023","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0144","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S1569-1993(23)00429-0","article-title":"Long-term efficacy and safety of Elexacaftor\/Tezacaftor\/Ivacaftor ETI) in people with cystic fibrosis (PWCF) \u2265 50 years of age in a real-world setting","volume":"22","author":"Welsner","year":"2023","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0049","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S1569-1993(24)00378-3","article-title":"Long-term safety and effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor (ETI): a 48-week observational study in a single reference centre","volume":"23","author":"Fragoso","year":"2024","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0077","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S1569-1993(24)00180-2","article-title":"Ws12.06 Elexacaftor\/Tezacaftor\/Ivacaftor improves iron status and is associated with correction of systemic inflammation and improvement of nutritional status: a one-year prospective multicentre study","volume":"23","author":"Lobbes","year":"2024","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1327958","article-title":"One year of treatment with Elexacaftor\/Tezacaftor\/Ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes","volume":"10","author":"Castaldo","year":"2024","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jcf.2026.02.015_bib0014","doi-asserted-by":"crossref","first-page":"S310","DOI":"10.1016\/S1569-1993(23)01504-7","article-title":"Cholesterol levels increase on elexacaftor-tezacaftor-ivacaftor therapy but remain within acceptable ranges","volume":"22","author":"Boyle","year":"2023","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.jcf.2026.02.015_bib0004","series-title":"Emerging research in cough, cystic fibrosis and bronchiectasis","first-page":"A7091","article-title":"Finger on the pulse: a single center snapshot of cardiovascular health in adults with cystic fibrosis","author":"Auth","year":"2024"},{"key":"10.1016\/j.jcf.2026.02.015_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2024.112425","article-title":"*Impact of CFTR modulator therapy on body composition as assessed by thoracic computed tomography: a follow-up study*","volume":"123","author":"Navas-Moreno","year":"2024","journal-title":"Nutrition"},{"issue":"5","key":"10.1016\/j.jcf.2026.02.015_bib0122","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jada.2008.02.020","article-title":"Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review","volume":"108","author":"Stallings","year":"2008","journal-title":"J Am Diet Assoc"},{"issue":"1","key":"10.1016\/j.jcf.2026.02.015_bib0021","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/jpm.2008.9690","article-title":"Study design, precision, and validity in observational studies","volume":"12","author":"Carlson","year":"2009","journal-title":"J Palliat Med"},{"issue":"5","key":"10.1016\/j.jcf.2026.02.015_bib0054","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.02.015_bib0096","series-title":"Diet and exercise in cystic fibrosis","first-page":"11","article-title":"Disordered eating and body image in cystic fibrosis","author":"Quick","year":"2015"},{"issue":"9","key":"10.1016\/j.jcf.2026.02.015_bib0097","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257852","article-title":"Covid-19 pandemic restrictions continuously impact on physical activity in adults with cystic fibrosis","volume":"16","author":"Radtke","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jcf.2026.02.015_bib0145","doi-asserted-by":"crossref","DOI":"10.7861\/fhj.2020-0205","article-title":"The impact of Covid-19 shielding on the wellbeing, mental health and treatment adherence of adults with cystic fibrosis","volume":"8","author":"Westcott","year":"2021","journal-title":"Future Healthc J"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:47:10Z","timestamp":1781884030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326000445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":120,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1569199326000445"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.02.015","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes to serum lipids, BMI and body composition in adults with cystic fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor (ETI): A scoping review","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}